|Articles|July 21, 2017

GB Sciences Signs Consulting Services Agreement with Worldwide Clinical Trials, Inc.

GB Sciences, Inc. announced it has signed a consulting services agreement with Worldwide Clinical Trials, Inc. to assess the company's intellectual property portfolio and help with pre-IND planning for its cannabis-based formulations. Pre-IND consulting services will be performed by Michael F. Murphy, MD, PhD, chief medical and scientific officer (CMSO) of Worldwide Clinical Trials, Inc.

Read the full release here.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Trending on Applied Clinical Trials Online

GB Sciences Signs Consulting Services Agreement with Worldwide Clinical Trials, Inc.

Related Content

Vaccine Trials at an Inflection Point: Operational, Regulatory, and Public Trust Challenges

ACT Brief: Cross-Asset Site Partnerships, Vaccine Trial Standardization, and Ovarian Cancer Care Gaps

A Shot in the Arm to Traditional Vaccine Trial Strategy

SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years

ACT Brief: Site-First Technology Strategy, AI Data Harmonization Architecture, and Obesity Trial Retention

Trending on Applied Clinical Trials Online

The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck

ACT Brief: Cross-Asset Site Partnerships, Vaccine Trial Standardization, and Ovarian Cancer Care Gaps

SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years

Patient Engagement Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention

A Shot in the Arm to Traditional Vaccine Trial Strategy